Medicus Pharma is focusing on key clinical milestones for its lead asset, SkinJect, in 2025. SkinJect, a non-invasive treatment for basal cell carcinoma (BCC), utilizes a patented micro-needle array technology. The company is also planning to expand its drug pipeline, according to CEO Raza Bokhari.
SkinJect's Progress in Basal Cell Carcinoma
SkinJect targets the over 5 million new cases of BCC diagnosed annually in the US. Following Phase 1 trial results showing complete clinical responses in six out of 13 patients, Medicus is currently conducting a Phase 2 trial involving 60 patients across nine US sites. The company aims to hold a Type C meeting with the FDA in the second quarter of 2025 to secure fast-track designation for SkinJect, a crucial step toward initiating a pivotal study. Medicus also plans to expand patient recruitment globally, including in the Asia-Pacific region and the Middle East, to support the program's advancement.
Expanding Applications and Pipeline
Beyond BCC, Medicus is leveraging its technology to address other non-melanoma skin diseases, such as actinic keratosis and squamous cell carcinoma in situ. The company is also exploring veterinary applications, particularly squamous cell carcinoma in horses, aiming to capitalize on orphan drug designation opportunities. Since its public debut in 2023, Medicus Pharma has raised $21.1 million to support its clinical trials and pipeline expansion.
Strategic Partnerships
Medicus Pharma is actively seeking partnerships with larger pharmaceutical companies to advance SkinJect. "Our goal is to advance SkinJect through proof of concept and position it for collaboration or acquisition by a larger partner that excels in commercialization," Bokhari stated. The company is also exploring opportunities to acquire novel assets to broaden its portfolio of dermatological treatments.
